Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesZYUS Life Sciences Corporation

ZYUS Life Sciences Corporation

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.35 CAD 0.03 ( 9.38%)
Last update at 2026-11-03T14:30:00Z
VOLUME
2810
Market Cap
50.45M

Momentum Score

…

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.35
Low
0.35
High
52 Week Price Range
0.44
Low
0.87
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ZYUS Life Sciences Corporation is an early-stage Canadian life sciences company listed on the TSX Venture with limited public disclosure of its operations and pipeline. Long-term growth may depend on progress in research and development, regulatory approvals and successful commercialization or licensing that could support revenue. Investors may find exposure to early-stage biotech upside attractive but should monitor milestone delivery and capital needs.

Key risks include clinical and execution uncertainty, significant financing and dilution risk, low share liquidity and regulatory obstacles that could delay or prevent commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.32
Dividend Yield
-
Revenue TTM
0.47M
Revenue Per Share
0.01
Gross Profit TTM
-1.03M
Debt / Equity
-
ROE
-3516.83%
Net Debt
7.59M
ROCE
542.84%
Diluted EPS TTM
-0.46

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -35.89M -48.44M -24.71M -23.57M
Net income -33.80M -42.59M -24.66M -23.45M
Selling general administrative 9.33M 12.60M 9.45M 13.11M
Gross profit 0.13M 0.17M -0.23M 0.14M
Reconciled depreciation 2.96M 3.11M 4.04M 3.78M
Operating income -14.70M -17.19M -16.30M -22.77M
Interest expense 0.76M 3.27M 5.24M 2.74M
Tax provision -2.09M -5.85M -0.06M -0.12M
Net interest income -1.08M -3.85M -5.46M -2.74M
Total revenue 0.48M 0.35M 0.30M 0.21M
Total operating expenses 15.18M 17.54M 16.59M 22.98M
Cost of revenue 0.35M 0.18M 0.53M 0.06M
Total other income expense net -20.11M -27.40M -2.96M 1.94M
Net income from continuing ops -33.80M -42.59M -24.66M -23.45M
Breakdown 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31
Total assets 14.67M 41.63M 64.71M
Intangible assets - 12.32M 35.39M
Other current assets 0.19M 0.87M 1.61M
Total liab 20.02M 18.51M 59.97M
Total stockholder equity -5.34M 23.11M 4.74M
Capital stock 156.70M 154.09M 92.67M
Retained earnings -173.99M -140.19M -97.60M
Good will 0.00M 5.87M 5.87M
Cash 1.90M 3.98M 0.21M
Total current liabilities 17.38M 13.24M 14.27M
Net debt 7.59M 2.81M 31.49M
Short long term debt 9.12M 6.15M 0.90M
Total current assets 3.36M 9.39M 6.27M
Short term investments 0.00M 1.87M 0.00M
Net receivables 0.05M 0.16M 0.20M
Long term debt 0.37M 0.64M 30.80M
Inventory 0.63M 2.04M 4.20M
Accounts payable 4.48M 3.44M 8.51M
Non currrent assets other 0.15M 0.15M 0.16M
Non current assets total 11.31M 32.24M 58.45M
Capital lease obligations 2.67M 3.02M 3.21M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 1.87M 4.64M -0.59M -4.99M
Net borrowings 2.66M - - -
Total cash from financing activities 5.97M 17.14M 9.63M 14.61M
Net income -33.80M -42.59M -24.66M -23.45M
Change in cash -2.08M 3.77M -0.54M -7.24M
Begin period cash flow 3.98M 0.21M 0.75M 7.99M
End period cash flow 1.90M 3.98M 0.21M 0.75M
Total cash from operating activities -9.88M -18.01M -9.57M -16.86M
Issuance of capital stock 3.31M 0.00M 0.17M 0.01M
Depreciation 2.96M 3.11M 4.04M 3.78M
Change to inventory 0.32M -0.02M 0.45M -0.17M
Change to account receivables 0.26M -0.35M 0.10M 0.33M
Capital expenditures 0.05M 0.28M 0.56M 4.99M
Change in working capital 1.69M -4.81M 2.62M 2.17M
Stock based compensation 0.41M 0.27M 0.11M 0.62M
Other non cash items 0.91M 5.99M 5.32M 2.46M
Free cash flow -9.92M -18.29M -10.13M -21.85M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ZYUS
ZYUS Life Sciences Corporation		 0.03
9.38%		 0.35 - - 108.48 4.41 140.29 -4.26
RX
Biosyent Inc.		 0.30
1.78%		 17.15 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 0.21
11.67%		 2.01 - 8.67 0.67 1.20 0.99 17.75
LSL
LSL Pharma Group Inc.		 0.01
1.64%		 0.31 20.75 - 1.88 1.89 2.85 10.19
ROMJ
Rubicon Organics Inc		 0.04
10.67%		 0.41 28.50 38.02 0.65 0.87 0.79 9.17

Profile*

ZYUS Life Sciences Corporation

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

Unit 204, Saskatoon, SK, Canada, S7N 4L8

888 651 9987

https://www.zyus.com

Name Title Year Born
Mr. Brent H. Zettl President, CEO, Secretary & Director 1962
Mr. John M. Hyshka Chief Financial Officer NA
Mr. Keith Carpenter CFA Chief Strategy & Investment Officer NA
Ms. Michelle Gursky Vice President of Legal Affairs NA
Dr. Lionel Marks de Chabris Chief Medical Officer NA
Mr. Tim Miller Director of Investor Relations & Capital Markets NA
Mr. Scott William Livingstone Vice President of Clinical Research NA
Dr. Julie Stakiw FRCPC, M.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…